Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.

Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS.

Target Oncol. 2018 Feb;13(1):61-68. doi: 10.1007/s11523-017-0542-1. Review.

2.

Hemodynamics associated with atrial fibrillation directly alters thrombotic potential of endothelial cells.

Simmers MB, Cole BK, Ogletree ML, Chen Z, Xu Y, Kong LJ, Mackman N, Blackman BR, Wamhoff BR.

Thromb Res. 2016 Jul;143:34-9. doi: 10.1016/j.thromres.2016.04.022. Epub 2016 Apr 27.

PMID:
27179130
3.

Factor XII full and partial null in rat confers robust antithrombotic efficacy with no bleeding.

Cai TQ, Wu W, Shin MK, Xu Y, Jochnowitz N, Zhou Y, Hoos L, Bentley R, Strapps W, Thankappan A, Metzger JM, Ogletree ML, Tadin-Strapps M, Seiffert DA, Chen Z.

Blood Coagul Fibrinolysis. 2015 Dec;26(8):893-902. doi: 10.1097/MBC.0000000000000337.

PMID:
26192114
4.

Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease.

Friedman EA, Ogletree ML, Haddad EV, Boutaud O.

Thromb Res. 2015 Sep;136(3):493-503. doi: 10.1016/j.thromres.2015.05.027. Epub 2015 May 28. Review.

5.

Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.

Xu Y, Cai TQ, Castriota G, Zhou Y, Hoos L, Jochnowitz N, Loewrigkeit C, Cook JA, Wickham A, Metzger JM, Ogletree ML, Seiffert DA, Chen Z.

Thromb Haemost. 2014 Apr 1;111(4):694-704. doi: 10.1160/TH13-08-0668. Epub 2013 Dec 12.

PMID:
24336918
6.

Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.

Woodruff RS, Xu Y, Layzer J, Wu W, Ogletree ML, Sullenger BA.

J Thromb Haemost. 2013 Jul;11(7):1364-73. doi: 10.1111/jth.12302.

7.

Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.

Chao H, Turdi H, Herpin TF, Roberge JY, Liu Y, Schnur DM, Poss MA, Rehfuss R, Hua J, Wu Q, Price LA, Abell LM, Schumacher WA, Bostwick JS, Steinbacher TE, Stewart AB, Ogletree ML, Huang CS, Chang M, Cacace AM, Arcuri MJ, Celani D, Wexler RR, Lawrence RM.

J Med Chem. 2013 Feb 28;56(4):1704-14. doi: 10.1021/jm301708u. Epub 2013 Feb 18.

PMID:
23368907
8.

Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.

Xu Y, Wu W, Wang L, Chintala M, Plump AS, Ogletree ML, Chen Z.

Blood Coagul Fibrinolysis. 2013 Apr;24(3):332-8. doi: 10.1097/MBC.0b013e32835e4219.

PMID:
23348428
9.

Quantification of circulating D-dimer by peptide immunoaffinity enrichment and tandem mass spectrometry.

Wang W, Walker ND, Zhu LJ, Wu W, Ge L, Gutstein DE, Yates NA, Hendrickson RC, Ogletree ML, Cleary M, Opiteck GJ, Chen Z.

Anal Chem. 2012 Aug 7;84(15):6891-8. doi: 10.1021/ac301494d. Epub 2012 Jul 19.

PMID:
22788854
10.

Duration of left ventricular assist device support: Effects on abnormal calcium cycling and functional recovery in the failing human heart.

Ogletree ML, Sweet WE, Talerico C, Klecka ME, Young JB, Smedira NG, Starling RC, Moravec CS.

J Heart Lung Transplant. 2010 May;29(5):554-61. doi: 10.1016/j.healun.2009.10.015. Epub 2009 Dec 31.

PMID:
20044278
11.

Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.

Bird JE, Giancarli MR, Allegretto N, Barbera F, Wong P, Schumacher WA, Ogletree ML, Seiffert D.

Thromb Res. 2008;123(1):146-58. doi: 10.1016/j.thromres.2008.03.010. Epub 2008 May 14.

PMID:
18479740
12.

Spontaneous atherothrombosis and medial degradation in Apoe-/-, Npc1-/- mice.

Welch CL, Sun Y, Arey BJ, Lemaitre V, Sharma N, Ishibashi M, Sayers S, Li R, Gorelik A, Pleskac N, Collins-Fletcher K, Yasuda Y, Bromme D, D'Armiento JM, Ogletree ML, Tall AR.

Circulation. 2007 Nov 20;116(21):2444-52. Epub 2007 Nov 5.

PMID:
17984379
13.

Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.

Schumacher WA, Seiler SE, Steinbacher TE, Stewart AB, Bostwick JS, Hartl KS, Liu EC, Ogletree ML.

Eur J Pharmacol. 2007 Sep 10;570(1-3):167-74. Epub 2007 Jun 5.

PMID:
17597608
14.

Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.

Wong PC, Crain EJ, Watson CA, Jiang X, Hua J, Bostwick JS, Ogletree ML, Schumacher WA, Rehfuss R.

J Cardiovasc Pharmacol. 2007 May;49(5):316-24.

PMID:
17513951
15.

Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats.

Schumacher WA, Bostwick JS, Ogletree ML, Stewart AB, Steinbacher TE, Hua J, Price LA, Wong PC, Rehfuss RP.

J Pharmacol Exp Ther. 2007 Jul;322(1):369-77. Epub 2007 Apr 9.

PMID:
17420297
16.

Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice.

Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, Ogletree ML, Seiffert DA.

J Thromb Haemost. 2006 Sep;4(9):1982-8.

17.

Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.

Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA.

J Thromb Haemost. 2006 Feb;4(2):403-10.

18.

Effects of remifentanil on the contractility of failing human heart muscle.

Ogletree ML, Sprung J, Moravec CS.

J Cardiothorac Vasc Anesth. 2005 Dec;19(6):763-7.

PMID:
16326302
19.

Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.

Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D.

J Thromb Haemost. 2005 Apr;3(4):695-702. Epub 2005 Feb 23.

20.

Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.

Sutton JC, Bolton SA, Davis ME, Hartl KS, Jacobson B, Mathur A, Ogletree ML, Slusarchyk WA, Zahler R, Seiler SM, Bisacchi GS.

Bioorg Med Chem Lett. 2004 May 3;14(9):2233-9.

PMID:
15081015
21.

Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.

Bisacchi GS, Slusarchyk WA, Bolton SA, Hartl KS, Jacobs G, Mathur A, Meng W, Ogletree ML, Pi Z, Sutton JC, Treuner U, Zahler R, Zhao G, Seiler SM.

Bioorg Med Chem Lett. 2004 May 3;14(9):2227-31.

PMID:
15081014
22.

Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats.

Wang X, Feuerstein GZ, Xu L, Wang H, Schumacher WA, Ogletree ML, Taub R, Duan JJ, Decicco CP, Liu RQ.

Mol Pharmacol. 2004 Apr;65(4):890-6.

PMID:
15044618
23.

Synthesis of potent and highly selective inhibitors of human tryptase.

Slusarchyk WA, Bolton SA, Hartl KS, Huang MH, Jacobs G, Meng W, Ogletree ML, Pi Z, Schumacher WA, Seiler SM, Sutton JC, Treuner U, Zahler R, Zhao G, Bisacchi GS.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3235-8.

PMID:
12372541
24.

Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.

Sutton JC, Bolton SA, Hartl KS, Huang MH, Jacobs G, Meng W, Ogletree ML, Pi Z, Schumacher WA, Seiler SM, Slusarchyk WA, Treuner U, Zahler R, Zhao G, Bisacchi GS.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33.

PMID:
12372540
25.

Retro-binding thrombin active site inhibitors: identification of an orally active inhibitor of thrombin catalytic activity.

Iwanowicz EJ, Kimball SD, Lin J, Lau W, Han WC, Wang TC, Roberts DG, Schumacher WA, Ogletree ML, Seiler SM.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3183-6.

PMID:
12372529
26.

Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.

Das J, Kimball SD, Hall SE, Han WC, Iwanowicz E, Lin J, Moquin RV, Reid JA, Sack JS, Malley MF, Chang CY, Chong S, Wang-Iverson DB, Roberts DG, Seiler SM, Schumacher WA, Ogletree ML.

Bioorg Med Chem Lett. 2002 Jan 7;12(1):45-9.

PMID:
11738570
27.

Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.

Das J, Kimball SD, Reid JA, Wang TC, Lau WF, Roberts DG, Seiler SM, Schumacher WA, Ogletree ML.

Bioorg Med Chem Lett. 2002 Jan 7;12(1):41-4.

PMID:
11738569
28.

Characterization of thromboxane A2/prostaglandin endoperoxide receptors in aorta.

Zhang R, Ogletree ML, Moreland S.

Eur J Pharmacol. 1996 Dec 12;317(1):91-6.

PMID:
8982724
29.

Myocardial calcium-independent phospholipase A2 activity during global ischemia in isolated rabbit hearts.

Vesterqvist O, Sargent CA, Grover GJ, Ogletree ML.

Cardiovasc Res. 1996 Jun;31(6):932-40.

PMID:
8759249
30.

Dissociation of endothelial cell dysfunction and blood pressure in SHR.

Tesfamariam B, Ogletree ML.

Am J Physiol. 1995 Jul;269(1 Pt 2):H189-94.

PMID:
7631848
31.

Protective effect of the serotonin receptor antagonist cinanserin in two canine models of pacing-induced myocardial ischemia.

Grover GJ, Parham CS, Youssef S, Ogletree ML.

Pharmacology. 1995 May;50(5):286-97.

PMID:
7667390
32.

Dose-related cardioprotection by ifetroban in relation to inhibition of thrombosis and ex vivo platelet function.

Gomoll AW, Schumacher WA, Ogletree ML.

Pharmacology. 1995 Feb;50(2):92-110.

PMID:
7716179
33.

Failure of aspirin to interfere with the cardioprotective effects of ifetroban.

Gomoll AW, Ogletree ML.

Eur J Pharmacol. 1994 Dec 27;271(2-3):471-9.

PMID:
7705447
34.

Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs.

Gomoll AW, Grover GJ, Ogletree ML.

J Cardiovasc Pharmacol. 1994 Dec;24(6):960-8.

PMID:
7898080
35.

Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs.

Grover GJ, Schumacher WA, Ogletree ML.

J Cardiovasc Pharmacol. 1994 Sep;24(3):493-9.

PMID:
7528306
36.

Characterization of rabbit myocardial phospholipase A2 activity using endogenous phospholipid substrates.

Vesterqvist O, Sargent CA, Grover GJ, Warrack BM, DiDonato GC, Ogletree ML.

Anal Biochem. 1994 Mar;217(2):210-9.

PMID:
8203749
37.

Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.

Schumacher WA, Steinbacher TE, Heran CL, Seiler SM, Michel IM, Ogletree ML.

J Pharmacol Exp Ther. 1993 Dec;267(3):1237-42.

PMID:
8263785
38.

Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.

Schumacher WA, Heran CL, Steinbacher TE, Youssef S, Ogletree ML.

J Cardiovasc Pharmacol. 1993 Oct;22(4):526-33.

PMID:
7505353
40.

Effects of endogenous and exogenous lysophosphatidylcholine in isolated perfused rat hearts.

Sargent CA, Vesterqvist O, Ogletree ML, Grover GJ.

J Mol Cell Cardiol. 1993 Aug;25(8):905-13.

PMID:
8263961
41.

Isolation and identification of lysophosphatidylcholines as endogenous modulators of thromboxane receptors.

Phillipson DW, Tymiak AA, Tuttle JG, Hartl KS, Harper TW, Bolgar MS, Allen GT, Ogletree ML.

J Lipid Mediat. 1993 Jun;7(2):155-67.

PMID:
8400117
42.

Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.

Ogletree ML, Harris DN, Schumacher WA, Webb ML, Misra RN.

J Pharmacol Exp Ther. 1993 Feb;264(2):570-8.

PMID:
8437108
43.

Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys.

Schumacher WA, Steinbacher TE, Youssef S, Ogletree ML.

Prostaglandins. 1992 Nov;44(5):389-97.

PMID:
1301074
44.

Gastroprotective effects of thromboxane receptor antagonists.

Ogletree ML, O'Keefe EH, Durham SK, Rubin B, Aberg G.

J Pharmacol Exp Ther. 1992 Oct;263(1):374-80.

PMID:
1403799
45.

Effect of the phospholipase A2 inhibitors quinacrine and 7,7-dimethyleicosadienoic acid in isolated globally ischemic rat hearts.

Sargent CA, Vesterqvist O, McCullough JR, Ogletree ML, Grover GJ.

J Pharmacol Exp Ther. 1992 Sep;262(3):1161-7.

PMID:
1382129
46.

Correction of ischaemic brain acidosis with SQ29,548/1-benzylimidazole.

Pettigrew LC, Hazle JD, Gutierrez G, Smith CD, Ogletree ML.

Neurol Res. 1992 Sep;14(4):335-9.

PMID:
1360630
47.

Quantitation of lysophosphatidylcholine molecular species in rat cardiac tissue.

Vesterqvist O, Sargent CA, Taylor SC, Newburger J, Tymiak AA, Grover GJ, Ogletree ML.

Anal Biochem. 1992 Jul;204(1):72-8.

PMID:
1514697
48.
49.

Attenuation of the pulmonary vascular response to endotoxin by a thromboxane synthesis inhibitor (UK-38485) in unanesthetized sheep.

Henry CL Jr, Ogletree ML, Brigham KL, Hammon JW Jr.

J Surg Res. 1991 Jan;50(1):77-81.

PMID:
1987435
50.

Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep.

Montalescot G, Lowenstein E, Ogletree ML, Greene EM, Robinson DR, Hartl K, Zapol WM.

Circulation. 1990 Nov;82(5):1765-77.

PMID:
2146041

Supplemental Content

Loading ...
Support Center